BREAKING NEWS: Anthos Therapeutics’ Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab, Demonstrated a 67% Greater Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding 
Compared to Rivaroxaban in Patients with Atrial Fibrillation

For access to a press kit, please contact a member of the media team at info@anthostherapeutics.com.

Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

NEWS PROVIDED BY Anthos Therapeutics → November 12, 2023 08:15 ET Secondary Endpoints Also Showed a Highly Significant 74% Reduction in Major Bleeding and a 93% Reduction in Gastrointestinal (GI) Bleeding with Abelacimab These Results Triggered the Data Monitoring...

Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions

NEWS PROVIDED BY Anthos Therapeutics September 26, 2023 07:00 ET Study Participants May Transition from the Rivaroxaban Arm to Abelacimab in an Extension Study   CAMBRIDGE, Mass., September 26, 2023 (BUSINESS WIRE) – Anthos Therapeutics, Inc., a clinical stage...

Anthos Therapeutics to Present Four Posters at ISPOR 2023

NEWS PROVIDED BY Anthos Therapeutics May 05, 2023 08:00 ET Additional presentation spotlights GARDENIA registry design in patients with atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer Associated...

Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine

Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine  Abelacimab achieved a ~80% reduction in venous...